Nuclear factor-κB dimer exchange promotes a p21waf1/cip1 superinduction response in human T leukemic cells

被引:20
作者
Chang, PY [1 ]
Miyamoto, S [1 ]
机构
[1] Univ Wisconsin, Dept Pharmacol, Program Mol & Cellular Pharmacol, Med Sci Ctr 301, Madison, WI 53706 USA
关键词
D O I
10.1158/1541-7786.MCR-05-0259
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The nuclear factor-kappa B (NF-kappa B)/Rel transcription factors are recognized as critical apoptosis regulators. We reported previously that NF-kappa B contributes to chemoresistance of CEM human T leukemic cells in part through its ability to induce p21(waf1/cip1). Here, we provide evidence that sequential NF-kappa B-activating signals induce heightened NF-kappa B DNA binding and p21(waf1/cip1) induction in CEM and additional T leukemic cell lines. This response arises from exceedingly low basal expression of the p105/p50 NF-kappa B subunit encoded by the NFKB1 gene in these cell lines. An initial NF-rB activation event enhances the recruitment of p65 and ELF1 to the NFKB1 promoter, leading to p65- and ELF1-dependent synthesis of p105/p50, which promotes an exchange of NF-rB complexes to p50-containing complexes with an increased DNA-binding activity to certain NF-rB target elements. Subsequent stimulation of these cells with an anticancer agent, etoposide, results in augmented NF-kappa B-dependent p21(waf1/cip1) induction and increased chemoresistance of the leukemia cells. Thus, we propose that low basal NFKB1 expression coupled with sequential NF-kappa B activation events can promote increased chemoresistance in certain T leukemic cells.
引用
收藏
页码:101 / 112
页数:12
相关论文
共 92 条
[71]   Differential regulation of the HIV-1 LTR by specific NF-kappa B subunits in HSV-1-infected cells [J].
Schafer, SL ;
Hiscott, J ;
Pitha, PM .
VIROLOGY, 1996, 224 (01) :214-223
[72]   Myc suppression of the p21Cip1 Cdk inhibitor influences the outcome of the p53 response to DNA damage [J].
Seoane, J ;
Le, HV ;
Massagué, J .
NATURE, 2002, 419 (6908) :729-734
[73]   Signatures of the immune response [J].
Shaffer, AL ;
Rosenwald, A ;
Hurt, EM ;
Giltnane, JM ;
Lam, LT ;
Pickeral, OK ;
Staudt, LM .
IMMUNITY, 2001, 15 (03) :375-385
[74]  
SHEIKH MS, 1994, ONCOGENE, V9, P3407
[75]   Signaling pathways responsible for cancer cell invasion as targets for cancer therapy [J].
Sliva, D .
CURRENT CANCER DRUG TARGETS, 2004, 4 (04) :327-336
[76]  
SOLARY E, 1994, LEUKEMIA, V8, P792
[77]   Selective inhibition of apoptosis by TPA-induced differentiation of U937 leukemic cells [J].
Sordet, O ;
Bettaieb, A ;
Bruey, JM ;
Eymin, B ;
Droin, N ;
Ivarsson, M ;
Garrido, C ;
Solary, E .
CELL DEATH AND DIFFERENTIATION, 1999, 6 (04) :351-361
[78]   Mitochondria-targeting drugs arsenic trioxide and lonidamine bypass the resistance of TPA-differentiated leukemic cells to apoptosis [J].
Sordet, O ;
Rébé, C ;
Leroy, I ;
Bruey, JM ;
Garrido, C ;
Miguet, C ;
Lizard, G ;
Plenchette, S ;
Corcos, L ;
Solary, E .
BLOOD, 2001, 97 (12) :3931-3940
[79]  
Tan C, 2002, CANCER RES, V62, P1083
[80]   Inhibition of JNK activation through NF-κB target genes [J].
Tang, GL ;
Minemoto, Y ;
Dibling, B ;
Purcell, NH ;
Li, ZW ;
Karin, M ;
Lin, A .
NATURE, 2001, 414 (6861) :313-317